Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IPO Update: Protagonist, Gemphire, Kadmon Launches Fall Flat

Executive Summary

The three most recent biopharma IPOs are trading at or below their offering prices, but the average return for the 22 drug development firms that have gone public so far this year is holding steady at 11% -- thanks to a pair of super performers that have delivered triple-digit returns.

Advertisement

Related Content

Biopharma IPOs In 2016: Fewer Offerings, Better Returns As Firms Adjust To Market Realities
IPO Update: Novan, AC Immune End Summer Slowdown As Market Improves
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
IPO Update: With No New Offerings, Kadmon Steals The Spotlight
StemCells Inc. To Wind Down Operations After Phase II Failure

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097151

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel